US 11,925,646 B2
Agent for treating or preventing cancer, and combination of RF pathway inhibitor and MEK inhibitor for treating or preventing cancer
Takako Ooshio, Sapporo (JP); Masahiro Sonoshita, Sapporo (JP); Satoshi Ichikawa, Sapporo (JP); Yusuke Satoh, Sapporo (JP); and Kiyonaga Fujii, Fukuoka (JP)
Assigned to NATIONAL UNIVERSITY CORP. HOKKAIDO UNIVERSITY, Sapporo (JP); and Tsuzuki Educational Institute, Fukuoka (JP)
Filed by NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, Sapporo (JP); and Tsuzuki Educational Institute, Fukuoka (JP)
Filed on Feb. 25, 2022, as Appl. No. 17/680,972.
Claims priority of application No. 2021-029585 (JP), filed on Feb. 26, 2021.
Prior Publication US 2022/0280521 A1, Sep. 8, 2022
Int. Cl. A61K 31/525 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/525 (2013.01) [A61P 35/00 (2018.01)] 4 Claims
OG exemplary drawing
 
1. A method for treatment of pancreatic cancer comprising administering an effective amount of roseoflavin to a subject.